Final outcome analysis from TUXEDO-1 trial is out

Elisa Agostinetto shared a paper by Rupert Bartsch et al. on X:

“Now out the final outcome analysis from TUXEDO-1 trial.

T-DXd in patients with active brain metastases produced prolonged intra and extra cranial disease control.

With 26.5 months median follow-up, mPFS was 21 months and mOS not reached.”

Source: Elisa Agostinetto/X

Elisa Agostinetto is a Clinical Research Fellow at the Institute Jules Bordet in Brussels, Belgium. She is also a Resident in Medical Oncology at Humanitas Research Hospital in Milan, Italy. Agostinetto specializes in Breast Cancer and Immuno-Oncology.

Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab – deruxtecan in. HER2-positive breast cancer patients with active brain metastases.

Authors: Rupert Bartsch, Anna Sophie Berghoff, Julia Furtner, Maximilian Marhold, Elisabeth Sophie Bergen, Sophie Roider-Schur, Maximilian Johannes Mair, Angelika Martina Starzer, Heidrun Forstner, Beate Rottenmanner, Marie-Bernadette Aretin, Karin Dieckmann, Zsuzsanna Bago-Horvath, Helmuth Haslacher, Georg Widhalm, Aysegül Ilhan-Mutlu, Christoph Minichsdorfer, Thorsten Fuereder, Thomas Szekeres, Leopold Oehler, Birgit Gruenberger, Georg Pfeiler, Christian Singer, Ansgar Weltermann, Luzia Berchtold, and Matthias Preusser.